JP2023502182A5 - - Google Patents

Info

Publication number
JP2023502182A5
JP2023502182A5 JP2022554171A JP2022554171A JP2023502182A5 JP 2023502182 A5 JP2023502182 A5 JP 2023502182A5 JP 2022554171 A JP2022554171 A JP 2022554171A JP 2022554171 A JP2022554171 A JP 2022554171A JP 2023502182 A5 JP2023502182 A5 JP 2023502182A5
Authority
JP
Japan
Prior art keywords
ido
prodrug
liposome
liposome according
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022554171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502182A (ja
JP7859982B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/000044 external-priority patent/WO2021096542A1/en
Publication of JP2023502182A publication Critical patent/JP2023502182A/ja
Publication of JP2023502182A5 publication Critical patent/JP2023502182A5/ja
Priority to JP2025052649A priority Critical patent/JP2025092573A/ja
Application granted granted Critical
Publication of JP7859982B2 publication Critical patent/JP7859982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022554171A 2019-11-12 2020-11-12 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法 Active JP7859982B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025052649A JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962974086P 2019-11-12 2019-11-12
US62/974,086 2019-11-12
PCT/US2020/000044 WO2021096542A1 (en) 2019-11-12 2020-11-12 Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025052649A Division JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Publications (3)

Publication Number Publication Date
JP2023502182A JP2023502182A (ja) 2023-01-20
JP2023502182A5 true JP2023502182A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7859982B2 JP7859982B2 (ja) 2026-05-15

Family

ID=73835687

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554171A Active JP7859982B2 (ja) 2019-11-12 2020-11-12 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法
JP2025052649A Pending JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025052649A Pending JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Country Status (8)

Country Link
US (2) US12286403B2 (cg-RX-API-DMAC7.html)
EP (1) EP4041402A1 (cg-RX-API-DMAC7.html)
JP (2) JP7859982B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220100904A (cg-RX-API-DMAC7.html)
CN (2) CN118286450A (cg-RX-API-DMAC7.html)
AU (2) AU2020384481B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159783A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021096542A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
WO2025121339A1 (ja) * 2023-12-04 2025-06-12 株式会社アンビシオン リポソーム剤、nkt細胞活性化剤、医薬組成物、およびこれらの用途
CN119792580A (zh) * 2025-01-02 2025-04-11 浙江大学 ID3 mRNA脂质纳米颗粒制备方法及在眼角膜疾病治疗中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
EP1773846A4 (en) 2004-07-13 2008-10-08 Univ British Columbia INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス, インコーポレイテッド Ido阻害剤
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
PT104158B (pt) 2008-08-18 2011-02-24 Univ Do Minho Aplicação da monooleína como novo lípido adjuvante em lipofecção
US8934953B2 (en) 2011-05-04 2015-01-13 Meridian Medical Systems, Llc Dual mode temperature transducer with oxygen saturation sensor
CN103857384B (zh) 2011-06-06 2017-07-11 大学健康网络 用于合成卟啉‑磷脂结合物的方法
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
BR112015022462A8 (pt) 2013-03-15 2019-11-26 Bristol Myers Squibb Co inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CN105777770B (zh) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
SG10201912394VA (en) 2015-07-15 2020-02-27 Celator Pharmaceuticals Inc Improved nanoparticle delivery systems
PE20180928A1 (es) 2015-07-24 2018-06-08 Newlink Genetics Corp Sales y profarmacos de 1-metil-d-triptofano
WO2017023667A1 (en) 2015-07-31 2017-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunostimulatory nanocarrier
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
CN108472245A (zh) 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
EP3400218A4 (en) 2016-01-08 2019-09-18 Euclises Pharmaceuticals, Inc. COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
US9624185B1 (en) 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CN109310702A (zh) 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
CN108424434B (zh) * 2017-02-13 2020-07-28 四川大学 氯喹胆固醇衍生物及其制备方法和用途
CA3063932A1 (en) * 2017-05-18 2018-11-12 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
WO2019057123A1 (zh) * 2017-09-20 2019-03-28 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN110025789A (zh) * 2019-04-01 2019-07-19 东南大学 一种药物磷脂化合物及其药物组合物和应用

Similar Documents

Publication Publication Date Title
GRALLA et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules
JP2024515650A5 (cg-RX-API-DMAC7.html)
JP5645340B2 (ja) 活性成分を含有するカチオンリポソームの投与方法
JP2024040167A5 (cg-RX-API-DMAC7.html)
EP2025337A1 (en) External pharmaceutical composition
CA2300695A1 (en) Novel compositions for the delivery of negatively charged molecules
JP2023513698A5 (cg-RX-API-DMAC7.html)
WO2002002078A2 (en) Improved liposomal camptothecins and uses thereof
US6770653B2 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US10584113B2 (en) Methylphenidate-prodrugs, processes of making and using the same
EP2266626A1 (en) Composition for external application comprising transcription factor decoy as active ingredient
TWI853940B (zh) 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
US11241448B2 (en) Methods for cancer therapy
JP2010510327A (ja) エンドキシフェンの方法および組成物
Plosker Pegylated liposomal doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma
RS51252B (sr) Upotreba alopurinola za lečenje palmarno-plantarne eritrodizestezije
US20250025489A1 (en) Methods of vaccination in premalignant settings
Jivan et al. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo
JP2023514324A5 (cg-RX-API-DMAC7.html)
CN101437505A (zh) 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途
EP1102594B1 (fr) Utilisation de chlorure de sodium pour reduire la toxicite gastro-intestinale des derives de la camptothecine
Igarashi et al. Distribution of lipid microsphere preparations
US20250064784A1 (en) Liposome composition comprising liposomal prodrug of mitomycin c and methods of treatment
US20230113802A1 (en) Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs
JPH07126164A (ja) 持効性抗真菌剤